Detalhe da pesquisa
1.
Ring A/B-Modified 17ß-Hydroxywithanolide Analogues as Antiproliferative Agents for Prostate Cancer and Potentiators of Immunotherapy for Renal Carcinoma and Melanoma.
J Nat Prod
; 84(12): 3029-3038, 2021 12 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34851111
2.
Withanolides from Aeroponically Grown Physalis peruviana and Their Selective Cytotoxicity to Prostate Cancer and Renal Carcinoma Cells.
J Nat Prod
; 80(7): 1981-1991, 2017 07 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-28617598
3.
Effects of cucurbitacins on cell morphology are associated with sensitization of renal carcinoma cells to TRAIL-induced apoptosis.
Apoptosis
; 17(1): 79-89, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21928090
4.
Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow.
J Immunol
; 182(7): 4328-38, 2009 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19299733
5.
Small-Molecule Natural Product Physachenolide C Potentiates Immunotherapy Efficacy by Targeting BET Proteins.
Cancer Res
; 81(12): 3374-3386, 2021 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33837043
6.
A cell-based high-throughput screen to identify synergistic TRAIL sensitizers.
Cancer Immunol Immunother
; 58(8): 1229-44, 2009 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-19089423
7.
Cytotoxic and other withanolides from aeroponically grown Physalis philadelphica.
Phytochemistry
; 152: 174-181, 2018 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-29775868
8.
17ß-Hydroxywithanolides as Sensitizers of Renal Carcinoma Cells to Tumor Necrosis Factor-α Related Apoptosis Inducing Ligand (TRAIL) Mediated Apoptosis: Structure-Activity Relationships.
J Med Chem
; 60(7): 3039-3051, 2017 04 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-28257574
9.
Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer.
Cancer Res
; 63(1): 207-13, 2003 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12517799
10.
The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis.
Ann N Y Acad Sci
; 1059: 160-7, 2005 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-16382051
11.
Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity.
Cancer Res
; 75(24): 5260-72, 2015 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26494122
12.
Increased secretory leukocyte protease inhibitor (SLPI) production by highly metastatic mouse breast cancer cells.
PLoS One
; 9(8): e104223, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25110884
13.
Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex.
Mol Cancer Res
; 8(5): 729-38, 2010 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-20442297
14.
Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity.
Cancer Res
; 69(16): 6615-23, 2009 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19654302
15.
NK cells use NKG2D to recognize a mouse renal cancer (Renca), yet require intercellular adhesion molecule-1 expression on the tumor cells for optimal perforin-dependent effector function.
J Immunol
; 177(4): 2575-83, 2006 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16888019
16.
Reduction of the antiapoptotic protein cFLIP enhances the susceptibility of human renal cancer cells to TRAIL apoptosis.
Cancer Immunol Immunother
; 54(5): 499-505, 2005 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-15614529
17.
Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
J Immunol
; 168(7): 3484-92, 2002 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-11907109
18.
The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP.
Blood
; 102(1): 303-10, 2003 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12637321